Elite Pharmaceuticals, Inc.

Represented Elite Pharmaceuticals, Inc. (AMEX:ELI), a pharmaceutical company principally engaged in the development of oral, controlled release products, in a private placement of $20 million of Series C Preferred Stock to institutional investors.